Carol Brosgart Net Worth

Carol Brosgart biography

Dr. Carol L. Brosgart M.D. serves as Independent Director of the Company. Dr. Brosgart serves on the boards of privately held companies and public, not-for-profit, domestic and global health organizations. She is a member of the Board of Directors of Galmed Pharmaceuticals, Ltd. (headquartered in Tel Aviv, Israel); Abivax, (headquartered in Paris, France), and Intrivo Diagnostics Diagnostics, (headquartered in California). She also is the Chair of Enochian’s Scientific Advisory Board on HBV Cure and Intrivo Diagnostics Diagnostic’s Scientific Advisory Board on COVID-19 diagnostic tests. Previously, she served as a member of Tobira Therapeutics’ Board of Directors from September 2009 until Allergan acquired it in November 2016; and, she was formerly on the Board of Juvaris, a vaccine company until Bayer Company acquired its assets. She is a consultant to Allergan, Dynavax, and a number of biotechnology companies in the areas of liver disease and infectious diseases. Dr. Brosgart is the Chair of the Scientific Advisory Committee for Hepion (formerly “ContraVir”), a biotechnology company working in the area of HBV Cure, NASH and Hepatocellular Carcinoma. She also serves on the Board of the American Liver Foundation (ALF) and on the ALF Medical and Scientific Advisory Board, Northern California Chapter, the Executive Committee of the Forum for Collaborative Research, and the Steering Committee of the HBV Cure Group at the Forum. She is a member of the Board of the Hepatitis B Foundation (HBF); serves on the Medical and Scientific Advisory Committee of the Hepatitis B Foundation; and, is the Research Integrity Officer for the Hepatitis B Foundation and the Baruch S. Blumberg Institute. Dr. Brosgart received a B.S. in Community Medicine from the University of California, Berkeley and received an M.D. from the University of California, San Francisco.

What is the salary of Carol Brosgart?

As the Independent Director of Enochian Biosciences Inc, the total compensation of Carol Brosgart at Enochian Biosciences Inc is $77,797. There are 10 executives at Enochian Biosciences Inc getting paid more, with Mark Dybul having the highest compensation of $1,964,450.

How old is Carol Brosgart?

Carol Brosgart is 69, he's been the Independent Director of Enochian Biosciences Inc since 2019. There are no older and 10 younger executives at Enochian Biosciences Inc.

What's Carol Brosgart's mailing address?

Carol's mailing address filed with the SEC is C/O ENOCHIAN BIOSCIENCES INC., 9480 NE 2ND AVENUE #73, MIAMI, FL, 33138.

Insiders trading at Enochian Biosciences Inc

Over the last 7 years, insiders at Enochian Biosciences Inc have traded over $2,106,789 worth of Enochian Biosciences Inc stock and bought 552,919 units worth $3,888,612 . The most active insiders traders include Gregg H Alton, Rene Sindlev, and Serhat Gumrukcu. On average, Enochian Biosciences Inc executives and independent directors trade stock every 91 days with the average trade being worth of $35,881. The most recent stock trade was executed by Serhat Gumrukcu on 18 May 2022, trading 253,493 units of ENOB stock currently worth $2,027,944.

What does Enochian Biosciences Inc do?

enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.

Enochian Biosciences Inc executives and stock owners

Enochian Biosciences Inc executives and other stock owners filed with the SEC include:

• Mark Dybul,
  Executive Vice Chairman of the Board, Principal Executive Officer
• Luisa Puche,
  Chief Financial Officer
• Dr. Mark R. Dybul M.D.,
  Chief Exec. Officer & Director
• Luisa Puche,
  Chief Financial Officer
• Evelyn D'An,
  Independent Director
• James Sapirstein,
  Independent Director
• Carl Sandler,
  Independent Director
• Henrik Gronfeldt-Sorensen,
  Director
• Rene Sindlev,
  Independent Chairman of the Board
• Gregg Alton,
  Independent Director
• Carol Brosgart,
  Independent Director
• Dr. François Binette M.Sc., Ph.D.,
  Exec. VP for R&D
• Greg Duczynski Ph.D.,
  Sr. VP for Clinical Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Tung Nguyen,
  Head of Molecular Biology
• Dr. Wenshi Wang,
  Sr. VP of Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Francois Binette,
  Executive VP for R&D
• Jayne Mc Nicol,
  Director
• Eric Jean Marie Leire,,
  
• Carl Forest Sandler,
  
• Serhat Gumrukcu,
  10% owner
• Anderson Wittekind William,
  
• Science Llc Weird,